Tamtam Try Tamtam free
Memorial Sloan Kettering Cancer Center logo

Memorial Sloan Kettering Cancer Center account plan

Comprehensive cancer care research

At a glance

Memorial Sloan Kettering is a New York cancer-only academic centre with FY2025 operating revenues of $8,530.4 million and 21,702 staff.

Memorial Sloan Kettering Cancer Center (MSK) is a New York tax-exempt 501(c)(3) academic cancer centre that combines Memorial Hospital for Cancer and Allied Diseases, the Sloan Kettering Institute for Cancer Research, the Gerstner Sloan Kettering Graduate School and a captive insurer. It treated 76,325 patients in 2025, in Manhattan, across its Regional Network and by telemedicine. In FY2025 (year ended December 31, 2025) total operating revenues were $8,530.4 million and operating expenses $8,578.3 million, a loss from operations of $47.9 million, while total net assets reached $11,046.1 million. Total staff was 21,702 at end-2025. MSK publishes no 10-K: it reports to bondholders through audited statements and DAC disclosures.

Business units

Strategic priorities

Expanding patient access
MSK states a long-term financial strategy centered on expanding patient access, strengthening operational discipline and supporting mission-driven growth. The Regional Network and telemedicine (328,499 visits in 2025) carry a growing share of activity.
Getting value from Epic
The Epic electronic health record went live in the first quarter of 2025; MSK credits first-half 2026 results partly to efficiencies realized through Epic.
Data, AI and computational oncology
The CEO expects cancer to be the area of greatest AI impact in healthcare, citing an MSK-trained model that predicts outcomes better than genomic data or staging; compute capacity is the stated bottleneck.
Precision oncology and immunotherapy
MSK sequences tumors and finds a target about 45 to 47 percent of the time, and the new Immuno-Oncology Program builds on checkpoint blockade, CAR T and cancer vaccines.
Early detection and interception
The Chief Scientific Officer wants to double down on finding and intercepting precancer using databases of hundreds of thousands of people; MSK also promotes screening and its online genetic risk tool, MSK Catch.
A $6 billion philanthropic campaign
MSK aims to raise $6 billion by 2030 to fund growth while staying an independent institution.

Latest results

For the first six months of 2026 MSK reported an excess of operating revenues over expenses of $216.6 million and an operating cash flow margin of 8.9% (statement of August 14, 2026). Operating revenues increased 11.5% versus the first half of 2025, or 9.9% excluding nonrecurring COVID Relief funding and payor settlement payments, driven by higher patient activity. Adjusted operating expenses, which exclude incremental Epic implementation costs, increased 7.0% on personnel costs and drug prices. This follows FY2025, when operating expenses rose to $8,578.3 million and turned a 2024 operating income of $202.2 million into a $47.9 million loss. MSK gives no numerical guidance.

Investments and deals

2025 DASNY bond issues
MSK issued $215.0 million DASNY 2025 Series 1 and $256.6 million DASNY 2025 Series 2 bonds, whose proceeds fund hospital equipment, capital projects and internal-use software; long-term debt and finance leases were $3,632.1 million at year-end 2025.
Facilities and equipment capex
Purchases of property and equipment were $444.9 million in 2025 (2024: $469.0 million), construction-in-progress was $550.4 million and construction and capital commitments of $316.2 million were outstanding.
Internal-use software
Capitalised computer software rose to $438.9 million from $310.8 million in 2025, alongside the Epic implementation.
Pension-annuity reinsurance
A framework agreement signed in February 2026 would reinsure pension annuities through the captive MSKI; it awaits regulatory approvals.

Challenges and risks

Cost growth outpacing revenue in 2025
Compensation and fringe benefits reached $4,286.2 million and purchased supplies and services $3,693.4 million, producing a 2025 operating loss of $47.9 million; personnel costs and industrywide drug-price increases remained the main pressures in 2026.
Government payor exposure
Medicare (32%) and Medicaid (6%) are a large share of hospital revenue and the audit flags that future program changes or funding cuts could have an adverse impact; Medicare cost reports are settled only through 2018.
Commercial payor concentration
Commercial insurers provide 60% of hospital revenue, and receivables are concentrated on Empire Health Choice (18%) and UnitedHealthcare (15%).
Capacity and compute constraints
Bed occupancy reached 98% in 2025, and the CEO says research projects that could take two weeks take five months for lack of computing capacity.
Access to costly therapies
The CEO says 80 percent of people who need CAR T cannot get it because of the cost.

What leadership says

“The challenge I would say is is GPUs.”

Selwyn M. Vickers, President and Chief Executive Officer · Talks at Goldman Sachs, recorded July 30, 2025, published October 7, 2025, on MSK's AI and data work

“building for the future. One in which we continue to flourish as an independent institution with global influence, delivering exceptional cancer care and pioneering innovative research.”

Selwyn M. Vickers, President and Chief Executive Officer · Message from the chairman and president, MSK Annual Report 2025

“I believe we need to really double down on that idea.”

Ross Levine, Chief Scientific Officer · MSK News interview, June 5, 2026, on intercepting precancer

“At MSK, it's team science. The sum is greater than the parts.”

Ross Levine, Chief Scientific Officer · MSK News interview, June 5, 2026

Where a supplier can help

Research computing capacity
The CEO names GPUs as the binding constraint on MSK's AI and computational oncology priority, a fit for compute, cloud and data-infrastructure providers.
Epic optimisation and internal-use software
MSK credits Epic efficiencies for its 2026 recovery and is funding internal-use software from its 2025 bonds, room for EHR optimisation, integration and analytics partners.
Throughput and capacity
With bed occupancy at 98% and a strategy built on expanding patient access, scheduling, patient-flow and Regional Network operations tools address a stated constraint.
Supply and drug-cost control
Purchased supplies and services of $3,693.4 million and industrywide drug-price increases tie into the operational-discipline priority, a fit for procurement, pharmacy and supply-chain offers.
Early detection programmes
The interception priority and MSK Catch rely on large population datasets and germline testing, an opening for diagnostics, data-analysis and patient-engagement suppliers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Memorial Sloan Kettering Cancer Center?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Memorial Sloan Kettering Cancer Center

What does Memorial Sloan Kettering do?

MSK is a cancer-only academic institution that combines patient care at Memorial Hospital, research at the Sloan Kettering Institute and training through the Gerstner Sloan Kettering Graduate School. It treated 76,325 patients in 2025.

What is Memorial Sloan Kettering's revenue?

Total operating revenues were $8,530.4 million in FY2025, with a loss from operations of $47.9 million. In the first half of 2026 operating revenues rose 11.5% and MSK posted a $216.6 million operating surplus.

How many employees does Memorial Sloan Kettering have?

Total staff was 21,702 at end-2025, including 4,691 registered nurses and 1,435 hospital attending staff.

Who leads Memorial Sloan Kettering?

Selwyn M. Vickers is President and CEO and Scott M. Stuart is Board Chair. Jeffrey Drebin is Chief Physician Executive and Ross Levine Chief Scientific Officer.

What is Memorial Sloan Kettering's strategy?

MSK focuses on expanding patient access, operational discipline and mission-driven growth, with research priorities in precision oncology, immunotherapy, AI and early detection. A $6 billion campaign by 2030 funds that growth.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)